Drug discovery

#Cell and gene therapy #Cell and Gene Therapy Catapult #Collaboration #Drug discovery

CGT Catapult’s creating opportunities in UK cell and gene therapy 

The Cell and Gene Therapy (CGT) Catapult has today published its Annual Review 2021, highlighting its key initiatives and impact in creating opportunities and investment in the UK cell and gene therapy industry.  2021 has reportedly emphasised the strength of the UK cell and gene therapy industry which experienced… Read More

#News

#Antibody #Biologics #Biosciences #Drug discovery

Twist Bioscience acquires Abveris to bolster biopharma capabilities  

Twist Bioscience has acquired Abveris, which will offer Twist comprehensive antibody discovery and characterisation services using its DiversimAb family of hyperimmune mouse models, the output of which can be humanised using the Twist antibody optimisation solution to develop biologics for rapid clinical advancement.   Emily Leproust, CEO and co-founder of Twist Bioscience, believes that the addition of the Abveris discovery… Read More

#News

#Drug development #Drug discovery #GlobalData #siRNA #Therapeutics

Chinese pharma companies eye strategic alliances for therapeutics

The overall potential of siRNA-based therapeutics has attracted Chinese pharma companies to tap opportunities and bring promising innovative therapies across the globe, according to reporting by GlobalData. Against this backdrop, the Chinese pharma companies have increased their focus towards the siRNA pipeline through strategic alliances.  China pharma… Read More

#News #Trending News

Human brain
#Drug development #Drug discovery #Healthcare #Neuroscience #Pharmaceuticals

NICE approves drug which treats EDS caused by narcolepsy 

Jazz Pharmaceuticals’ Sunosi (solriamfetol) has been issued a positive Final Appraisal Document (FAD) from the National Institute for Health and Care Excellence (NICE), recommending the drug for adults with excessive daytime sleepiness (EDS) caused by narcolepsy.1  When is solriamfetol needed?  Solriamfetol is recommended as an option for treating EDS… Read More

#News #Trending News

#Drug discovery #Healthcare #Innovation

Ten start-ups selected for KQ Labs accelerator programme

Ten start-up companies working at the interface of biomedical and data science are to receive personalised mentoring and coaching as part of the KQ Labs accelerator programme, run by the Francis Crick Institute and funded by the medical research charity LifeArc in partnership with Cancer Research UK and UK SPINE.  What will… Read More

#News #Start-up Zone

#Covid-19 #Drug discovery #Pharmaceuticals

Newly launched antiviral nasal spray reduced Covid in ICU by 80%  

Amcyte Pharma has launched Nasitrol nasal spray for sinus irrigation in the US. In an independent clinical trial published in the peer-reviewed International Journal of General Medicine, Nasitrol reduced Covid transmission among ICU staff by nearly 80%, suggesting it could represent a safe and effective prophylaxis to prevent transmission of Covid-19.   What… Read More

#News

#Cancer research #Clinical trials #Drug discovery #Oncology #T-Cells #Tumours

HOOKIPA advances to Phase II trials for treatment of head and neck cancer 

HOOKIPA Pharma is advancing HB-201 to Phase II to be evaluated in combination with pembrolizumab as first or second-line treatment for Human Papillomavirus Positive 16 (HPV16+) squamous cell head and neck cancers (HNSCC).   Interim Phase I data in heavily pre-treated patients continue to show HB-200 monotherapy (both… Read More

#News

#Data #Drug development #Drug discovery #Genomics #Research study #Tuberculosis

Largest ever global TB study identifies genetic causes of drug resistance 

The Comprehensive Resistance Prediction for Tuberculosis International Consortium (CRyPTIC) research project has reportedly collected the largest ever global dataset of clinical M. tuberculosis samples from across the world consisting of 15,211 samples from 27 countries on five continents.  Using a new quantitative test for drug resistance and… Read More

#News #Trending News

#Drug discovery #Research study

New stroke clot-buster drug shows ‘exciting potential’ in mice 

A novel clot-busting drug formulated and tested by University of Manchester scientists is able to effectively restore blood flow in the brains of mice, opening the door for a safer and more effective stroke treatment, according to the study published in the journal Blood.  The compound, an… Read More

#News

#Cell therapy #Drug development #Drug discovery #Immunology

Bone marrow backup needed to tackle respiratory infections 

Scientists at the Francis Crick Institute have found how the immune system triggers an ‘emergency’ dendritic cell response during infection, with dendritic cells at the site of infection being reinforced by new cells which travel from the bone marrow.   Dendritic cells have an important role in the… Read More

#News #Trending News

#AI #AI / data analytics / healthtech / informatics #Chemistry #Drug discovery

Machine learning needs Big Data to revolutionise drug discovery

Machine learning (ML) holds the promise to revolutionise drug discovery. By integrating vast datasets into predictive models, ML will help researchers arrive at the optimal candidate compounds more quickly, disrupting the long cycle times of preclinical discovery research. DEL technology is unmatched in its ability to produce ultra-large datasets. By… Read More

#Editor's Choice #Exclusive Content #Intelligence #News #Opinion #Trends & Analysis

#Drug discovery #Laboratory data

Insightful Science acquisition to expand products 

Insightful Science, the software company enabling the cloud for scientific discovery, has completed the transaction to acquire LabArchives.  LabArchives is a research data management application, serving 600,000 scientists in academic, non-profit and commercial organisations. It automates data capture, enhances collaboration, creates seamless workflows, and improves lab efficiency.  Matt Dunie,… Read More

#News

#Biologics #Drug development #Drug discovery #Immuno-oncology #Monoclonal antibodies

The potential of small molecules and biologics for new therapeutics 

Listen to this article on the DDW Podcast: Dr Seth Lederman is a physician-scientist, entrepreneur, and CEO of Tonix Pharmaceuticals. He talks to Lu Rahman about Tonix Pharmaceuticals’ mission to research and manufacture small molecules and biologics for the treatment of CNS and immunological conditions.  Since its formation in 2011, Tonix Pharmaceuticals… Read More

#Business & Investment #Exclusive Content #News

#Drug development #Drug discovery #Pharmaceuticals

Doloromics appoints President and Chief R&D Officer

Doloromics has appointed Dr. Chris Flores as their new President and Chief Research and Development Officer. In this role, Dr. Flores will be responsible for leading the Doloromics portfolio of drug discovery and development programmes, two of which are scheduled to launch in early 2022, while building relationships with strategic partners and collaborators… Read More

#News